$8.22
-0.02 (-0.24%)
USD · as of 2026-08-18 · marketstack
Clinical trials
catalyst calendar across sponsors →Studies where SGHT is the lead sponsor, as filed with ClinicalTrials.gov. Completion dates are the sponsor's own projected windows and are revised as a study runs. Active studies first, then completed and stopped — newest readout first within each.
15 interventional · 2 observational · 13 with posted results
Held by 11 tracked-famous managers (AQR CAPITAL MANAGEMENT LLC, Qube Research & Technologies Ltd, D. E. Shaw & Co., Inc., Squarepoint Ops LLC, CITADEL ADVISORS LLC, +6 more) · FINRA short interest 5.5 days to cover (settled 2026-07-31) · insider 90d: 1 buys / 0 sells · government filings 180d: none disclosed
| Study | Phase | Status | Interventions | Conditions | Enrollment | Primary completion | Readout in | Updated |
|---|---|---|---|---|---|---|---|---|
| A Study of the Helix Surgical System in Primary Open-Angle Glaucoma (POAG) and Cataract (HELIX)NCT06948773≥ 20% change from baseline in mean IOP at the 3-month post-operative endpointOpen-label · Treatment | Not applicable | Active, not recruiting | Device: Helix Surgical System | Primary Open Angle Glaucoma, Cataract | 25 | 2026-09-30 | in 42 d | 2026-07-07 |
| OMNI 3.1 Surgical System in Subjects With Primary Open-Angle GlaucomaNCT06991270Primary Effectiveness EndpointOpen-label · Treatment | Not applicable | Recruiting | Device: OMNI 3.0 Surgical System | Primary Open Angle Glaucoma | 25 | 2026-08-31 | in 12 d | 2026-01-14 |
| TearCare MGX™ System With and Without Warming HoldNCT07365735Mean difference between eyes in Meibomian Gland Secretion Score (MGSS)Randomized · Double-masked · Treatment | Not applicable | Completed | Device: localized heat therapy | Meibomian Gland Dysfunction (Disorder) | 21 | 2026-05-19actual | — | 2026-06-05 |
| A Clinical Trial Comparing the OMNI Surgical System to Standard Medical Treatment in Patients With Primary Open Angle GlaucomaNCT06407973Subjects with a ≥ 20% reductionRandomized · Open-label · Treatment | Phase 4 | Terminatedsponsor's stated reason: Business decision by the Sponsor | Device: OMNI Surgical System · Drug: Latanoprost plus adjunctive glaucoma medication | Primary Open Angle Glaucoma | 2 | 2025-01-20actual | — | 2025-01-29 |
| Safety And Effectiveness Of The TearCare® System In The Treatment Of The Signs And Symptoms Of Dry Eye Disease (SAHARA)NCT04795752results2025-11-24Tear Break-Up TimeRandomized · Single-masked · TreatmentStudy Protocol and Statistical Analysis Plan ↗ | Not applicable | Completed | Device: TearCare System · Drug: Cyclosporine Ophthalmic 0.05% Ophthalmic Emulsion | Dry Eye, Meibomian Gland Dysfunction | 345 | 2024-09-23actual | — | 2025-11-24 |
| An Observational Multicenter Clinical Study To Assess The Safety And Effectiveness Of The OMNI® Surgical System In Pseudophakic Eyes With Primary Open Angle Glaucoma (ORION 2.0)NCT04872348results2025-05-11observationalChange in Intraocular Pressure (IOP)Study Protocol and Statistical Analysis Plan ↗ | — | Completed | Device: OMNI® Surgical System | Glaucoma, Open-Angle | 28 | 2023-11-02actual | — | 2025-05-22 |
| A Clinical Study To Assess The Safety And Effectiveness Of The OMNI® Surgical SystemNCT05044793results2025-01-22observationalPrimary Safety EndpointStudy Protocol and Statistical Analysis Plan ↗ | — | Completed | Device: OMNI® Surgical System | Glaucoma, Open-Angle | 70 | 2023-08-21actual | — | 2025-01-22 |
| Study of OMNI Surgical System and iStent for Eyes With OAG (Trident)NCT04658095results2025-10-27Mean Change in Unmedicated DIOP From Baseline at the 12-month Postoperative ExaminationRandomized · Open-label · TreatmentStudy Protocol and Statistical Analysis Plan ↗ | Not applicable | Terminatedsponsor's stated reason: Business Decision | Device: Canaloplasty and trabeculotomy with the OMNI system., iStent inject, Canaloplasty | Glaucoma, Open-Angle | 10 | 2022-11-18actual | — | 2025-10-27 |
| Study of OMNI System in OAG (GEMINI)NCT03861169results2024-08-14Change in Mean Unmedicated Diurnal IOPOpen-label · TreatmentStudy Protocol and Statistical Analysis Plan ↗ | Not applicable | Completed | Device: Transluminal viscoelastic delivery and trabeculotomy | Open Angle Glaucoma | 209 | 2021-05-04actual | — | 2024-08-14 |
| A Prospective, Multicenter Study of the OMNI® Surgical System in Pseudophakic Eyes With Open Angle GlaucomaNCT04465630results2022-06-07Change in Intraocular Pressure (IOP)Open-label · TreatmentStudy Protocol and Statistical Analysis Plan ↗ | Not applicable | Terminatedsponsor's stated reason: Sponsor Decision | Device: OMNI® Surgical System | Glaucoma, Open-Angle | 78 | 2021-03-02actual | — | 2022-06-28 |
| A Post-market Study Of Use Of The OMNI® Surgical System In Open Angle GlaucomaNCT04616573results2022-12-01Change in Unmedicated Diurnal Intraocular Pressure (DIOP)Randomized · Open-label · TreatmentStudy Protocol and Statistical Analysis Plan ↗ | Not applicable | Terminatedsponsor's stated reason: Sponsor decision | Device: OMNI® Surgical System, iStent inject | Glaucoma, Open-Angle | 1 | 2021-01-20actual | — | 2022-12-01 |
| TearCare System to Treat Dry Eye DiseaseNCT03857919results2025-10-01Change in Tear Break-Up Time (TBUT) From BaselineRandomized · Single-masked · TreatmentStudy Protocol and Statistical Analysis Plan ↗ | Not applicable | Completed | Device: TearCare, LipiFlow | Dry Eye, Meibomian Gland Dysfunction | 235 | 2020-02-17actual | — | 2025-10-01 |
| Pilot Study of TearCare System - Long-Term ExtensionNCT03804502results2025-10-28Mean Change in Tear Break-Up Time From Extension Study Baseline to Month 1Open-label · TreatmentStudy Protocol and Statistical Analysis Plan ↗ | Not applicable | Completed | Device: TearCare | Dry Eye Syndromes | 12 | 2019-05-21actual | — | 2025-10-28 |
| Safety and Effectiveness of the Sight Sciences VISCO™360 Versus SLT in Primary Open Angle GlaucomaNCT02928289results2025-09-24Mean Change From Baseline in Diurnal IOP at 12 Months (Measured in mm Hg)Randomized · Single-masked · TreatmentStudy Protocol ↗ · Statistical Analysis Plan ↗ | Not applicable | Terminatedsponsor's stated reason: Poor enrollment | Device: VISCO360 ab interno canaloplasty surgery, Selective Laser Trabeculoplasty (SLT) | Open-Angle Glaucoma | 29 | 2019-01-17actual | — | 2025-11-14 |
| Randomized Study of the Safety and Effectiveness of the TearCare System for the Signs and Symptoms of Dry Eye DiseaseNCT03502447results2025-09-29Mean Change in Tear Break-Up Time From Baseline to Month 1Randomized · Single-masked · TreatmentStudy Protocol and Statistical Analysis Plan ↗ | Not applicable | Terminatedsponsor's stated reason: Sponsor chose to change the study design. | Device: TearCare, Warm Compress and Lid Massage | Dry Eye Syndromes | 14 | 2018-12-04actual | — | 2025-09-29 |
| Study of the TearCare System in Dry Eye DiseaseNCT03588624results2025-09-11Mean Change in Tear Break-Up Time (TBUT) at 1-month From BaselineOpen-label · TreatmentStudy Protocol and Statistical Analysis Plan ↗ | Not applicable | Completed | Device: TearCare | Dry Eye | 29 | 2018-10-11actual | — | 2025-09-11 |
| A Pilot Study of the TearCare System in Adults With Dry Eye DiseaseNCT03006978results2025-10-15Mean Change in Tear Breakup Time From Baseline to Month 1Randomized · Open-label · TreatmentStudy Protocol and Statistical Analysis Plan ↗ | Not applicable | Completed | Device: TearCare, Warm Compress | Dry Eye | 24 | Feb 2017actual | — | 2025-10-15 |
Primary completion is the date the sponsor filed with the registry — their own projection, revised whenever they revise it, unless the row is marked actual.
Source: ClinicalTrials.gov, retrieved 2026-08-19